
The study compared the prevalence of pathogenic germline variants (PGVs) in head and neck cancer patients with guideline-based testing. It also evaluated the uptake of family variant testing. The study found that universal gene panel testing identified a PGV in 10.5% of head and neck cancer patients, and almost all of them would have been missed by current guideline-based testing. Only one patient had a change in care based on the identified PGV. The study suggests that head and neck cancer treatment decisions are not yet widely informed by germline alterations.
Like
Save
Share